That said, CMS reserves the right to request additional information for any application, which may impact the review timing and/or probability of a J-code or TDAPA. Both a J-code and an approved and effective TDAPA application are gating items for the outpatient commercial launch of DefenCath, which is currently slated for July 1. The company remains on schedule to commence our commercial launch for the in-patient setting on April 15. We have staffed and trained our field sales and medical affairs organizations and held a successful internal team launch meeting during the last week of February. The team we have built is deeply experienced and specialized with backgrounds in both infectious disease and nephrology spanning both the in-patient and outpatient settings of care.